
Opinion|Videos|May 7, 2024
Highlighting the Available CDK4/6 Inhibitors
Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
3
Emavusertib-Based Therapy Produces Responses in BTK Inhibitor–Treated Primary CNS Lymphoma
4
Online GLP-1 Sellers Often Skip Clinician Oversight, Secret Shopper Study Finds
5












































































































